论文部分内容阅读
1990年7月至1993年2月,我们将49例重症肺心病随机分成三组,对比观察藻酸双酯钠(PSS)+654-2、654-2及常规治疗的治疗效果。PSS+654-2组20例,男7例、女13例,年龄56±12岁,病程23±10岁。654-2组11例,男3例、女8例,年龄54±11岁,病程20±8岁。对照组18例,男6例、女12例,年龄57±10岁,病程18±9岁。 1.治疗方法:对照组:吸氧、抗炎、止咳、解痉平喘、强心、利尿等综合治疗。PSS+654-2组:在上述基础上加用PSS100mg、654-2 10mg入低分子右旋糖酐250ml静滴(每分钟30滴),日1次。654-2组:在对照组用药基础上加用654-2 10mg入低分子右旋糖酐250ml静滴(30滴/min),日1次。
July 1990 to February 1993, we have 49 cases of severe pulmonary heart disease were randomly divided into three groups, compared the efficacy of sodium alginate (PSS) + 654-2,654-2 and conventional treatment. PSS + 654-2 group of 20 patients, 7 males and 13 females, aged 56 ± 12 years, duration of 23 ± 10 years. 654-2 group 11 cases, 3 males and 8 females, aged 54 ± 11 years, duration of 20 ± 8 years. Control group, 18 cases, 6 males and 12 females, aged 57 ± 10 years, duration of 18 ± 9 years. 1. Treatment: control group: oxygen, anti-inflammatory, cough, antispasmodic asthma, cardiac, diuretic and other comprehensive treatment. PSS + 654-2 group: add PSS100mg and 654-2 10mg into 250ml low molecular dextran intravenous drip (30 drops per minute) once daily on the above basis. 654-2 group: In the control group based on the use of 654-2 10mg into the low molecular weight dextran 250ml intravenous infusion (30 drops / min), on the 1st.